Piramal Pharma Limited has informed the Exchange regarding Appointment of Mr. Amit Jain as Non- Executive Director of the company w.e.f. May 14, 2025.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma's board met on May 14, 2025 and approved audited financial results for Q4 and FY25. Standalone revenue grew 20.4% YoY to Rs. 5,285.71 cr, with net profit rising 76.7% to Rs. 691.40 cr (FY25 EPS: Rs. 5.22 vs Rs. 3.05). Consolidated revenue rose 12% to Rs. 9,151.18 cr, while consolidated net profit jumped to Rs. 91.13 cr from Rs. 17.82 cr. The board recommended a final dividend of Rs. 0.14 per share, subject to shareholder approval. On the board front, Carlyle's representative Mr. Neeraj Bharadwaj resigned citing personal commitments, and was replaced by Mr. Amit Jain as Non-Executive, Non-Independent Director. Independent Director Mr. Jairaj Purandare was also re-appointed for a second 5-year term effective Feb 9, 2026. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion on the results.
Strong FY25 earnings with sharp profit growth and a modest dividend declaration are positive for shareholders. The director changes are routine Carlyle nominee rotation, with no governance red flags, and should not materially affect the stock.